- Trials with a EudraCT protocol (1,804)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
1,804 result(s) found for: Placebo comparator.
Displaying page 7 of 91.
EudraCT Number: 2004-000139-27 | Sponsor Protocol Number: A509 1018 | Start Date*: 2004-09-14 | |||||||||||
Sponsor Name:Pfizer AB | |||||||||||||
Full Title: A Phase 3, Double-Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter Study of the Efficacy, Safety, and Tolerability of Fixed Combination Torcetrapib/Atorvastatin Administered Orall... | |||||||||||||
Medical condition: Mixed dyslipidemia (Frederickson Types IIa and IIb) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005271-15 | Sponsor Protocol Number: 20050179 | Start Date*: 2007-07-18 |
Sponsor Name:Amgen Inc | ||
Full Title: A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment with Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women with Low Bone Mineral De... | ||
Medical condition: Postmenopausal osteoporosis /osteopenia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2004-001482-17 | Sponsor Protocol Number: F1D-MC-HGKQ(b) | Start Date*: 2004-10-15 |
Sponsor Name:Eli Lilly and Company | ||
Full Title: Olanzapine Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated with Bipolar I disorder. | ||
Medical condition: Manic or Mixed Episodes Associated with Bipolar I Disorder | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: LT (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-003581-25 | Sponsor Protocol Number: APA-III | Start Date*: 2015-05-26 |
Sponsor Name:University Hospital Tuebingen | ||
Full Title: Anti-inflammatory pulmonal therapy of CF-patients with Amitriptyline and Placebo - Randomised, double-blind, placebo-controlled cohort trial | ||
Medical condition: Amitriptyline reduces ceramide concentrations in bronchial epithelial cells and reduces cell death and reduces the deposition of DNA on the respiratory epithelium. This reduction promotes the elimi... | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2012-005726-30 | Sponsor Protocol Number: CURES-IL1T-OT-1236 | Start Date*: 2014-04-28 |
Sponsor Name:Charité - Universitätsmedizin | ||
Full Title: A multi-center, double-blind placebo-controlled parallel group phase II study of the efficacy and safety of rilonacept in subjects with cold contact urticaria (CCU) | ||
Medical condition: cold contact urticaria (CCU) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-004343-92 | Sponsor Protocol Number: 21559 | Start Date*: 2021-06-23 |
Sponsor Name:Bayer Healthcare LLC. | ||
Full Title: Randomized, Controlled, Double-blind, Placebo-controlled, Multi-center Hypothesis-finding Trial to Compare the Efficacy and Safety of a 10% Naproxen Gel vs. a 2.32% Diclofenac Diethylamine Gel and ... | ||
Medical condition: acute strains, sprains or bruises of the lower extremities following blunt trauma | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-019381-90 | Sponsor Protocol Number: p57 | Start Date*: 2010-07-05 | |||||||||||||||||||||
Sponsor Name:universiteit Maastricht | |||||||||||||||||||||||
Full Title: an fMRI study on the effects of NicVAX and placebo on Central Nervous System activation and behaviour following a nicotine challenge | |||||||||||||||||||||||
Medical condition: Nicotine addiction/smoking | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||||||||||||
Trial protocol: NL (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001555-14 | Sponsor Protocol Number: NBK272/1/2021 | Start Date*: 2023-01-05 |
Sponsor Name:Medical University of Gdańsk | ||
Full Title: Assessment of the effect of Wharton's jelly mesenchymal stem cell preparation (WJMSCs) in the treatment of fibrotic interstitial lung diseases | ||
Medical condition: fibrotic interstitial lung disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: PL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000228-20 | Sponsor Protocol Number: 16012020001 | Start Date*: 2020-08-28 |
Sponsor Name:Medical University of Graz | ||
Full Title: Probiotic dietary Intervention in Polycystic Ovary Syndrome – A Randomized Controlled Trial | ||
Medical condition: Polycystic Ovary Syndrome (PCOS) is a hormonal and metabolic disorder affecting up to 20 percent of women worldwide, depending on diagnostic criteria. A very common definition of PCOS based on the ... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-000868-18 | Sponsor Protocol Number: 202018 | Start Date*: 2019-12-02 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A 24-week, phase 3, multicentre, randomised, double-blind, efficacy and safety study, comparing GSK3196165 with placebo and with sarilumab, in combination with conventional synthetic DMARDs, in par... | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) PL (Completed) LT (Completed) ES (Completed) BE (Completed) CZ (Completed) HU (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000346-33 | Sponsor Protocol Number: D361BC00001 | Start Date*: 2020-07-20 |
Sponsor Name:AstraZeneca AB | ||
Full Title: Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing Efficacy and Safety of Capivasertib+Abiraterone Versus Placebo+Abiraterone as Treatment for Patients with DeNovo Metastatic Ho... | ||
Medical condition: Metastatic Hormone-Sensitive Prostate Cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: NL (Trial now transitioned) BG (Trial now transitioned) CZ (Trial now transitioned) GB (GB - no longer in EU/EEA) SK (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2006-004146-16 | Sponsor Protocol Number: EFC6224 | Start Date*: 2007-01-22 |
Sponsor Name:sanofi-aventis recherche & développement | ||
Full Title: A multi-national, multi-center, double blind, placebo-controlled, parallel group, fixed dose efficacy and safety study of SR58611A 350 mg twice daily vs. placebo in adults with Major Depressive Dis... | ||
Medical condition: Major Depressive Disorder | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) BE (Completed) FI (Completed) GR (Completed) EE (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-002461-37 | Sponsor Protocol Number: PEPITES | Start Date*: 2015-12-17 | |||||||||||
Sponsor Name:DBV Technologies | |||||||||||||
Full Title: A double-blind, placebo-controlled, randomized phase III pivotal trial to assess the efficacy and safety of peanut epicutaneous immunotherapy with viaskin peanut in peanut-allergic children | |||||||||||||
Medical condition: Peanut Allergy | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-003793-94 | Sponsor Protocol Number: EFC5574 | Start Date*: 2006-10-20 |
Sponsor Name:sanofi-aventis recherche & développement | ||
Full Title: An Eight-Week, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled Study, with Escitalopram as an Active Control, to Evaluate the Efficacy, Safety and Tolerability of a Saredut... | ||
Medical condition: to Evaluate the Efficacy, Safety and Tolerability of a Saredutant 100 mg Dose Once Daily, in Elderly Patients with Major Depressive Disorder (MDD) | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) SE (Completed) FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-001877-13 | Sponsor Protocol Number: TMT107235 | Start Date*: 2006-08-24 |
Sponsor Name:GlaxoSmithKline Research & Development Ltd | ||
Full Title: A randomised, double-blind, double-dummy, parallel-group, placebo-controlled study comparing correlates of brain functional activation before and after treatment with placebo, active comparator par... | ||
Medical condition: Major Depressive Disorder | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2018-001926-25 | Sponsor Protocol Number: IM011046 | Start Date*: 2019-02-11 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Subjects with Moderate-to-Severe Plaque Psoriasis | |||||||||||||
Medical condition: Moderate-to-Severe Plaque Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) FR (Prematurely Ended) ES (Ongoing) DE (Completed) PL (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005047-28 | Sponsor Protocol Number: CS0011-A-U301 | Start Date*: 2007-03-23 | |||||||||||
Sponsor Name:DAIICHI SANKYO PHARMA DEVELOPMENT | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO AND ACTIVE COMPARATOR-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF RIVOGLITAZONE AS MONOTHERAPY TREATMENT OF TYPE 2 DIABETES MELLITUS | |||||||||||||
Medical condition: The current study will support an indication for rivoglitazone as oral monotherapy to improve glycemic control in subjects with type 2 diabetes mellitus not adequately controlled with diet and exer... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) LV (Completed) SK (Completed) AT (Completed) CZ (Completed) GB (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004216-70 | Sponsor Protocol Number: BM17864 | Start Date*: 2007-01-30 |
Sponsor Name:F.Hoffmann-La Roche Ltd. | ||
Full Title: A randomized, double-blind, parallel group, placebo-controlled (with open-label active comparator arm), dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of RO... | ||
Medical condition: Type 2 Diabetes Mellitus | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GR (Prematurely Ended) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-002331-34 | Sponsor Protocol Number: ALOFEC-2019 | Start Date*: 2022-11-08 | |||||||||||
Sponsor Name:FIMABIS | |||||||||||||
Full Title: A multicenter, randomized, double-blind Phase IIb study to evaluate the safety and efficacy of the intralesional administration of two doses of expanded allogeneic adipose tissue adult stem mesench... | |||||||||||||
Medical condition: Fecal incontinence | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004637-33 | Sponsor Protocol Number: FMLD-IOTRA-20_FIIIA | Start Date*: 2014-06-11 |
Sponsor Name:Laboratorios Farmalider S.A. | ||
Full Title: Clinical trial phase III, multicenter, randomised, double-blind, double-dummy, parallel treatment design, active-controlled and placebo, to evaluate the analgesic efficacy and safety of ibuprofen a... | ||
Medical condition: Moderate to severe pain following dental surgery. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
